Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | HPGD | P15428 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10125953 | 0.98 | ALDH1A1 (0.47) | NPC1ALDH1A1HPGDRAB9AKDM4E | |
| SCHEMBL10315412 | 0.90 | NPC1 (0.43) | NPC1ALDH1A1HPGDRAB9AKDM4E | |
| SCHEMBL10125895 | 0.90 | NPC1 (0.51) | NPC1ALDH1A1HPGDRAB9AKDM4E | |
| SCHEMBL10315180 | 0.89 | ALDH1A1 (0.42) | NPC1ALDH1A1HPGDRAB9AKDM4E | |
| SCHEMBL10125981 | 0.88 | ALDH1A1 (0.49) | NPC1ALDH1A1HPGDRAB9AKDM4E | |
| SCHEMBL19369682 | 0.87 | NPC1 (0.51) | NPC1ALDH1A1HPGDRAB9AKDM4E | |
| SCHEMBL10125793 | 0.85 | ALDH1A1 (0.47) | NPC1ALDH1A1HPGDRAB9AKDM4E | |
| SCHEMBL10125959 | 0.85 | NPC1 (0.51) | NPC1ALDH1A1HPGDRAB9AKDM4E | |
| SCHEMBL10126089 | 0.85 | NPC1 (0.51) | NPC1ALDH1A1HPGDRAB9AKDM4E | |
| SCHEMBL28681367 | 0.84 | NPC1 (0.59) | NPC1ALDH1A1HPGDRAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119259-B2 | Quinoxaline derivative, and light-emitting element and electronic device using the same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-8119259-B2 | Quinoxaline derivative, and light-emitting element and electronic device using the same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20090140642-A1 | Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2009-06-04 | — | — | US | disclosed |
| US-20090140642-A1 | Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090140642-A1 | Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same | NDUFA11, NDUFA9, NDUFA12 | NPC1 4763/4885ALDH1A1 345/4885HPGD 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.